• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Biotech CEL-SCI Needs More Base Building

Let's review the charts and indicators.
By BRUCE KAMICH
Mar 09, 2021 | 11:17 AM EST
Stocks quotes in this article: CVM

During Friday's "Lightning Round" segment of Mad Money, one caller asked Jim Cramer about the biotech firm CEL-SCI Corp (CVM) : "I think this one is good," responded Cramer. This biotechnology company is involved in the research and development of immunotherapy products for the treatment of cancer, autoimmune and infectious diseases.

Let's check out the charts and indicators as the fundamentals are above my pay grade.  

In this daily bar chart of CVM, below, we can see that prices traded sideways in the $18-$12 area from late April to late January before exploding on the upside. Prices soared sharply to around $40 in a few days and since then prices have been slowly declining back to the breakout level or the top end of the consolidation pattern.
 
Prices are testing the rising 50-day moving average line and the positive 200-day moving average line intersects around $14. The trading volume surged in late January and early February but has since calmed down.
 
The On-Balance-Volume (OBV) line declined until late December but then turned up into the middle of February. The weakness in the OBV line since the middle of February seems to be some light liquidation or profit taking.
 
The Moving Average Convergence Divergence (MACD) oscillator has made a round trip from the zero line.  
 
 
In this weekly Japanese candlestick chart of CVM, below, we can see two large upper shadows above $25 telling us that traders rejected those prices. The rising 40-week moving average line intersects down around $15 and could well be tested in the days or weeks ahead.
 
The OBV line shows us a three-year rise and that is pretty constructive. The MACD oscillator turned sharply higher in January but is already narrowing.  
 
 
In this Point and Figure chart of CVM, below, we used daily price data and we can see a potential upside price target in the $24 area. 
 
 
 
In this second Point and Figure chart of CVM, below, we used weekly price data. Here the chart suggests the $10 area as a price target. 
 
 
 
Bottom line strategy: The daily bar chart of CVM looks like the recent rally in prices "happened overnight" but the weekly chart shows prices trending higher over the past three years. Big difference. The daily Point and Figure chart is bullish but the weekly chart is bearish. Confusing isn't it? I think the best course of action is for CVM to form a big base.
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual issues.

TAGS: Investing | Stocks | Technical Analysis | Trading | Biotechnology | Healthcare | Mad Money

More from Investing

I'm Going to Let the Air Out of a Fundamental Rating of Air Products

Bruce Kamich
May 25, 2022 3:30 PM EDT

APD got a "Buy" recommendation, but my analysis doesn't jibe.

As Pioneer Natural Resources Blazes a Trail Higher, We Have New Price Targets

Bruce Kamich
May 25, 2022 2:50 PM EDT

Here's our updated bullish strategy on PXD.

Home Depot's Charts Are Building Out Nicely

Bruce Kamich
May 25, 2022 1:24 PM EDT

Investors can measure out their long positions at these levels.

Sell the Rumor and Buy the News on Dick's Sporting Goods

Bruce Kamich
May 25, 2022 12:24 PM EDT

Wednesday's down to up move makes trading decisions more complex.

Toll Brothers: We're Going to Need a Bigger Base

Bruce Kamich
May 25, 2022 11:36 AM EDT

The homebuilder's charts need more base building for me to get more constructive.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:33 AM EDT PETER TCHIR

    Thoughts Ahead of the Fed Minutes

    Recent economic and earnings issues are convincing...
  • 02:24 PM EDT PAUL PRICE

    An Interesting Chart

    I'm betting heavily that stocks will be way up aga...
  • 10:10 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "Market Timing for Dummies"
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login